IO Biotech, Inc. 8K

IO Biotech engaged Raymond James as exclusive financial advisor for its strategic alternatives review and implemented a significant workforce reduction to cut costs.

On January 30, 2026, IO Biotech, Inc. announced that it has engaged Raymond James Associates, Inc. as its exclusive financial advisor to assist with the company’s previously disclosed exploration of strategic alternatives, and that, in parallel, it is implementing cost-containment and cash conservation measures, including a significant reduction in its workforce, in order to reduce operating expenses while this strategic review is underway.

Filing Facts

CIK

1865494

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-031987

Alert Tier

7